Kevin J. Bratton

Jazz Pharmaceuticals (EUSA Pharma USA), Inc. develops and markets biopharmaceutical products. The company was founded on November 7, 1980 and is headquartered in Princeton, NJ.

VJGJ, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.

Metrologic Instruments, Inc. provides laser and imaging bar code scanners including linear and omni-directional laser scanners, fixed position and in-counter scanners, area imagers and rugged mobile computers. The company was founded by C. Harry Knowles in 1968 and is headquartered in Blackwood, NJ.

Standard Diversified, Inc. is a holding company, which owns and operates subsidiaries in a variety of industries, including other tobacco products, insurance, and outdoor advertising. It operates through the following segments: Smokeless Products, Smoking Products, and NewGen Products. The Smokeless Product segment manufactures and markets moist snuff and contracts for and markets chewing tobacco products. The Smoking Products segment imports and markets cigarette papers, tubes, and related products; imports and markets finished cigars, MYO cigar tobaccos, and cigar wraps; and processes, packages, and markets pipe tobaccos. The NewGen Products segment trades e-cigarettes, e-liquids, vaporizers, and other related products; and distributes a wide assortment of vaping products to non-traditional retail outlets via VaporBeast and Vapor Shark. The company was founded by Martha C. Reider, Anne Cavanaugh and Richard C. Birkmeyer in 1990 and is headquartered in New York, NY.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.